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Abdominal aortic aneurysm (AAA) is a pathological dila-tation of the aorta that can result in rupture and death. It 
is a common disease among older people. A national screen-
ing program for 65-year-old men is being introduced in the 
United Kingdom, with the aim of reducing mortality from rup-
tured AAA by offering surgery to those with large aneurysms. 
However, surgery is not without risk, and the goals of pri-
mary prevention and medical treatment to slow progression 
are actively pursued through efforts to better understand the 
pathogenesis of AAA.
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Background—Abdominal aortic aneurysm (AAA) is a common cardiovascular disease among older people and demonstrates 
significant heritability. In contrast to similar complex diseases, relatively few genetic associations with AAA have been 
confirmed. We reanalyzed our genome-wide study and carried through to replication suggestive discovery associations 
at a lower level of significance.
Methods and Results—A genome-wide association study was conducted using 1830 cases from the United Kingdom, New 
Zealand, and Australia with infrarenal aorta diameter ≥30 mm or ruptured AAA and 5435 unscreened controls from 
the 1958 Birth Cohort and National Blood Service cohort from the Wellcome Trust Case Control Consortium. Eight 
suggestive associations with P<1×10−4 were carried through to in silico replication in 1292 AAA cases and 30 503 controls. 
One single-nucleotide polymorphism associated with P<0.05 after Bonferroni correction in the in silico study underwent 
further replication (706 AAA cases and 1063 controls from the United Kingdom, 507 AAA cases and 199 controls from 
Denmark, and 885 AAA cases and 1000 controls from New Zealand). Low-density lipoprotein receptor (LDLR) rs6511720 
A was significantly associated overall and in 3 of 5 individual replication studies. The full study showed an association that 
reached genome-wide significance (odds ratio, 0.76; 95% confidence interval, 0.70–0.83; P=2.08×10−10).
Conclusions—LDLR rs6511720 is associated with AAA. This finding is consistent with established effects of this variant on 
coronary artery disease. Shared causal pathways with other cardiovascular diseases may present novel opportunities for 
preventative and therapeutic strategies for AAA.  (Circ Cardiovasc Genet. 2013;6:498-504.)
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AAA shares many features with other cardiovascular dis-
eases. Lifestyle risk factors include tobacco use1,2 and inactiv-
ity.3 Coronary artery disease, cerebral vascular disease, and 
peripheral vascular disease are found at higher rates among 
people with AAA, suggesting that there are shared exposures 
or shared disease pathways.1,4–6 AAA exhibits significant heri-
tability and is observed to cluster in families.7 A family history 
of AAA confers a risk of disease that is comparable in effect 
size with cigarette smoking.4,5 The role of cholesterol and ath-
erosclerosis in AAA is not well understood. Atherosclerosis 
often accompanies AAA, but whether the association is 
causative is controversial.8 Higher levels of high-density 
lipoprotein-cholesterol are associated with protection against 
AAA,9,10 and raised serum total cholesterol is associated with 
increased risk.3,4 The effect of serum low-density lipoprotein 
(LDL) remains unclear, with some reports of increased risk 
but inconclusive meta-analyses.9–12 Genetic polymorphisms of 
LRP113, DAB2IP,14 and SORT115 were discovered to be associ-
ated with susceptibility to AAA in genome-wide association 
studies. CDKN2B-AS16–18 and IL6R19 were identified and con-
firmed with a high level of certainty in candidate-gene studies. 
Relatively few genetic risk factors for AAA have been identi-
fied to date, which is unexpected considering its heritability, 
complex pathogenesis, and similarity to other cardiovascular 
diseases for which many risk associations have been found. 
We reanalyzed our genome-wide association study with par-
ticular emphasis on limiting possible sources of experimen-
tal method-related false associations and carried through to 
replication newly identified putative associations at a lower 
threshold of discovery association.
Materials and Methods
Study Design and Participants
All participating centers had approval from appropriate local research 
ethics committees to conduct their studies, and all participants gave 
written informed consent. Identifiable information was not provided 
to collaborating researchers. The study adheres to the tenets of the 
Declaration of Helsinki. The study design has been described previ-
ously.13 A case–control genome-wide association study was carried 
out using 1830 cases from the United Kingdom, New Zealand, and 
Australia who had an infrarenal aorta diameter of ≥30 mm on trans-
abdominal ultrasound scan or a ruptured AAA and 5435 unscreened 
population controls from the 1958 Birth Cohort and National Blood 
Service cohort from the Wellcome Trust Case Control Consortium. 
The mean age of the cases was 73 years, and the median infrarenal 
aortic diameter was 4.6 cm. Median age of the Blood Transfusion 
Service cohort was 45 years, and participants from the 1958 Birth 
Cohort were aged 52 years at the time of genotyping. Associations 
with genomic inflation-corrected P<5×10−8 in additive model logistic 
regression were considered to be significant at a genome-wide level, 
and P values <1×10−4 were considered to be suggestive of an associa-
tion. The threshold of P<10−4 was chosen to be an order of magnitude 
greater than the original analysis to investigate putative associations 
that might be apparent after stringent quality control aimed at exclud-
ing artifactual false associations. A 2-stage replication study was con-
ducted. First, a representative single-nucleotide polymorphism (SNP) 
from each associated locus was carried through to an in silico replica-
tion study that comprised 452 cases and 27 712 controls from Iceland 
and 840 cases and 2791 controls from The Netherlands. Associations 
from known loci at CDKN2B-AS1, LRP1, and IL6R, and the previ-
ously investigated GPC6, were excluded from further analyses. SNPs 
were chosen for predicted compatibility with a Sequenom multiplex 
reaction. SNPs that showed significant association at P<0.05 after 
Bonferroni correction for multiple testing in stage 1 were carried 
through to a laboratory replication study of 706 cases and 1063 con-
trols from the United Kingdom (Belfast, Leeds, and Leicester) and 
507 cases and 199 controls from Viborg, Denmark. The same diag-
nostic criteria were used for cases in the replication studies as in the 
discovery study. Statistical significance at stage 2 also had P<0.05 af-
ter Bonferroni correction for multiple testing. Finally, to confirm any 
positive findings from stage 2, we used in silico data from a recent 
genome-wide association study of AAA.15 This New Zealand study 
consisted of 885 additional cases of AAA and 1000 additional con-
trols, none of which was included in the original genome-wide study.
Discovery Study Microarray Experiment  
and Genotyping
Cases were genotyped at the Wellcome Trust Sanger Institute us-
ing the Illumina Human670 Quad Custom version 1 bead chip, and 
the WTCCC2 common controls were genotyped using the Illumina 
1.2M Duo Custom version 1a bead chip. The raw idat data produced 
at the Sanger Institute were normalized and genotyped using the 
corrected robust linear mixture model crlmm package20 in R ver-
sion 2.14.0 on the Queen’s University Belfast High-Performance 
Computing Dell Cluster using SOCK parallelization in 4 batches of 
≈1900 individuals. Quality control steps are described in the online-
only Data Supplement.
Discovery Study Association Analysis
The genome-wide study was analyzed using an additive model which 
assumes that each extra copy of an allele contributes the same change 
in odds and that 2 copies of an allele confer twice the odds of 1 copy. 
The ancestry of participants was analyzed by principal components 
analysis (Methods in the online-only Data Supplement). The associa-
tion analysis was conducted using logistic regression with ancestry 
eigenvectors included as covariates for the 5 statistically significant 
axes to correct the analysis for residual population stratification. The 
analysis was performed using PLINK version 1.07.
Replication Stage Genotyping and Analysis
A Sequenom iPLEX was designed using MySequenom software 
and conducted according to the manufacturer’s protocols. Primer se-
quences are shown in Table III in the online-only Data Supplement. 
Briefly, a multiplex polymerase chain reaction was conducted on an 
ABI 9700 Dual 384-well thermal cycler, unincorporated dNTPs were 
neutralized using a shrimp alkaline phosphatase reaction, primer ex-
tension was conducted using the iPLEX termination mix and further 
cycling, and conditioning resin was added before nanodispensing 
and measurement of extension product on a Sequenom MassArray. 
Cluster plots were inspected using Typer 4.0 Software. In silico 
analyses were provided from Icelandic (452 cases and 27 712 con-
trols) and Dutch (840 cases and 2791 controls) AAA genome-wide 
association studies. Association P values from the Icelandic analyses 
were adjusted for population relatedness and potential population 
stratification by the genomic control factor (λ=1.143). The Dutch 
study did not require correction (λ=1)14 and was, therefore, used 
without correction in our study. LDL receptor (LDLR) rs6511720 
was genotyped as part of a Sequenom iPLEX in a UK replication 
group (729 cases and 1104 controls) and a replication group from 
Viborg, Denmark (496 cases and 176 controls). Twelve UK cases, 
25 UK controls, 6 Viborg cases, and 4 Viborg controls were excluded 
because of low genotyping rate (<90%). The remaining genotyping 
rate was 99.9%. 
The association analyses were conducted using additive model lo-
gistic regression in PLINK for the laboratory study with no covari-
ates. Data from the Iceland and Netherlands studies were analyzed 
in NEMO.21
The additional New Zealand genome-wide study (885 cases and 
1000 controls) was conducted using the Affymetrix SNP6 GeneChip 
array and tested for association between AAA and LDLR rs6511720 
using additive model logistic regression in PLINK. Full details of this 
study have been described previously.15
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Logistic regression analyses with adjustment for age (United 
Kingdom, Denmark, and New Zealand replication studies) and 
LDL-cholesterol (adjusted for statin use; New Zealand) were also 
conducted.
Meta-analysis
The results from the individual studies were combined using inverse 
variance-weighted meta-analysis in METASOFT. Between-study 
heterogeneity was investigated by estimating the heterogeneity index 
(I2) also in METASOFT. Fixed-effects and Han Eskin random-effects 
meta-analyses were conducted. In the absence of heterogeneity, a 
fixed-effects model was used, and in its presence, Han Eskin ran-
dom-effects model was used.22 Han Eskin meta-analysis is a form 
of random-effects meta-analysis for the use in genetic studies in the 
presence of heterogeneity.
Imputation
Targeted imputation of LDLR was carried out using IMPUTE223 with 
reference to all populations in The 1000 Genomes Project Phase 1 
integrated version 3 data release. Thirty Markov chain Monte Carlo 
iterations, including a burn in of 10 iterations and 40 conditioning 
states, were used. Population size (-Ne) was set to 20 000. Imputed 
regions were each 2 Mb in size. Visualization was performed using 
Locus Zoom.
Results
In the final discovery study, 1755 cases (1554 men and 201 
women) and 5314 controls (2706 men and 2608 women) were 
genotyped for 503 892 SNPs that passed all quality control 
thresholds. The final genotyping rate was 99.85%. A quantile–
quantile plot is shown in Figure II in the online-only Data 
Supplement.
No SNPs had association P values reaching genome-wide 
significance level in the discovery study. Twenty-three SNPs 
in 12 loci had suggestive association P values of <1×10−4 
(Figure 1; Table II in the online-only Data Supplement). 
Eight SNPs were carried through to in silico replication, one 
of which remained significant after Bonferroni correction for 
multiple testing (LDLR rs6511720 A; odds ratio [OR], 0.79 
[0.69–0.89]; P=2.34×10−4; Figure 2). The same allele was 
associated significantly in an independent laboratory repli-
cation (OR, 0.73 [0.57–0.94]; P=0.016; Table). Han Eskin 
random-effects meta-analysis of combined replication stages 
1 and 2 produced an OR of 0.78 (0.69–0.87; P=1.95×10−5) for 
rs6511720 A, and both the discovery and the replication steps 
give an OR of 0.78 (0.72–0.85), an association that reached 
genome-wide significance (P=6.97×10−9).
The additional New Zealand genome-wide study data set 
provided further independent replication of the association 
(OR, 0.68 [0.50–0.93]; P=4.8×10−3). The combination of the 
New Zealand results with the rest of the study by Han Eskin 
random-effects meta-analysis resulted in an OR of 0.76 (0.70–
0.83; P=2.08×10−10).
Age-adjusted analyses were performed for Denmark, United 
Kingdom, and New Zealand replication groups. The associations 
found in Denmark and New Zealand were statistically signifi-
cant after adjustment for age (Denmark: OR, 0.52 [0.36–0.77; 
P=8.9×10−4]; New Zealand: OR, 0.68 [0.50–0.93; P=0.016]). 
The UK replication group (which did not show association in 
unadjusted analysis) did not show association after adjustment 
for age (OR, 1.03 [0.82–1.29; P=0.80]; Table IV in the online-
only Data Supplement). Adjustment of the New Zealand analy-
ses for LDL-cholesterol (corrected for statin use) demonstrated 
that the association of LDLR and AAA was independent of 
LDL-cholesterol (adjusted OR, 0.69 [0.52–0.92]; P=0.012).
Discussion
We report that rs6511720 in LDLR is a novel genetic risk fac-
tor for AAA. The effect associated with this SNP is similar to 
that reported for LRP1, DAB2IP, IL6R, and SORT1. LDLR is 
Figure 1. Manhattan plot of abdominal aortic aneurysm genome-wide association study. Manhattan plot of discovery study showing 
genomic control-adjusted −log10 (P values) for additive model from logistic regression incorporating eigenvectors as covariates. High-
lighted single-nucleotide polymorphisms are the new confirmed locus (low-density lipoprotein receptor [LDLR]) and 4 previously detected 
loci (low-density lipoprotein–related protein 1 [LRP1; alpha-2-macroglobulin receptor]; CDKN2B antisense RNA 1 [CDKN2B-AS1]; DAB2 
interacting protein [DAB2IP]; and interleukin 6 receptor [IL6R])
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the simplest of a family of LDL-cholesterol cell surface recep-
tors24 that also includes the AAA-associated LRP1.13
LDLR rs6511720 is one of the most important LDL-
cholesterol–associated variants in genome-wide studies of 
lipid traits.25–31 Importantly, a relationship between AAA and 
LDL-cholesterol levels is not presently established. The most 
complete meta-analysis of the relationship was inconclu-
sive, and individual reports are inconsistent.9,32–34 Our report 
of association between LDLR polymorphism and AAA sus-
ceptibility suggests that either LDL-cholesterol is important 
in AAA pathogenesis or LDLR polymorphism has an effect 
on another causal pathway. The adjusted results of the New 
Zealand study suggest that the association is independent of 
LDL-cholesterol levels.
Despite this uncertainty, our finding is consistent with other 
knowledge of AAA pathogenesis. LDLR-knockout (Ldl−/−) 
mice are used as disease models for AAA.35 The same LDLR 
allele (rs6511720 A) that we report is associated with protec-
tion against AAA is also associated with protection against 
coronary artery25,28,29,36,37 and carotid artery atherosclerotic 
plaque formation.38 A recent meta-analysis of the use of lipid-
lowering therapy in AAA to reduce the rate of expansion has 
shown some benefit. This finding is consistent with LDL-
cholesterol having a direct role in AAA pathogenesis.34
We are aware of the limitations of this study. The strict 
quality control measures used in this analysis allowed us to 
identify the LDLR locus by excluding false-positive associa-
tions. We accepted the possibility of also excluding some true 
associations as a consequence. Meta-analysis of genome-wide 
association studies for AAA may offer a future opportunity 
to identify further AAA loci that have been excluded. The 
rs6511720 SNP was associated with AAA at a similar level 
in the original study analysis, as were many additional likely 
spurious associations. Although the LDLR locus could have 
been identified in the original discovery analysis at P<10−4, 
Bonferroni correction for the attempted replication of many 
additional putative associations would have vastly reduced the 
power to replicate true associations. The ORs in the Denmark 
and New Zealand studies were unaffected by adjustment for 
age, and the association remained significant after inclusion of 
age as a covariate in a logistic regression model. The UK rep-
lication study that showed no association with rs6511720 was 
unaffected by the inclusion of age in the logistic regression.
The use of the standard 3-cm definition of AAA has limita-
tions as a phenotype for genetic studies because it is arbitrary, 
and risk of AAA by this measure is affected by height and 
sex. Future studies might benefit from using a definition of 
AAA that incorporates an individual’s stature. Alternatively, 
longitudinal studies of disease progression have the poten-
tial to be useful, although different gene associations might 
be found to affect progression. Future studies to determine 
whether LDL-cholesterol levels are causal in the pathogen-
esis of AAA could use Mendelian randomization that would 
require prospective standardized collection of data for serum 
lipids and the use of lipid-lowering therapies. We do not have 
sufficient extra information to explore heterogeneity in the 
rs6511720 association. Possible causes for differences in 
the effect size between the components of the study include 
chance and gene–environment interactions because of differ-
ences in exposures (tobacco or lipid-lowering therapy) whose 
prevalence differs over time or between places and case–mix 
variation (whereby screening-detected AAA, elective surgical 
cases, and ruptured AAA are differently represented between-
study components). Two of the 6 component studies in this 
investigation did not show a significant association between 
rs6511720 A and AAA. This is similar to the situation in the 
3 other published genome-wide studies of AAA.13–15 Possible 
reasons for this include low power in individual component 
studies, type II error, and the winner’s curse.39 Our study made 
use of the Wellcome Trust Case Control Consortium shared, 
unscreened controls. The use of population controls offers the 
advantages of reduced testing for participants, shared costs 
between projects, and increased power because of the ready 
availability of participants. A potential drawback is a reduced 
effect size caused by the presence of a small number of people 
who would meet the case definition within the control group 
and the increased risk of type II errors.40
Our finding that LDLR polymorphism affects odds of AAA 
suggests that study of relationships between LDL-cholesterol 
Table.  LDLR rs6511720 A Allele
Sample Set Cases (n) Controls (n) Case AF Control AF OR (95% CI) P Value I 2
Discovery study 1755 5314 0.097 0.123 0.76 (0.67–0.86) 3.05×10-5 …
Stage 1 replication
  The Netherlands 840 2791 0.093 0.128 0.70 (0.59–0.83) 5.69×10−5 …
  Iceland 452 27 712 0.091 0.099 0.91 (0.72–1.15) 0.42 …
  Combined 1292 30 503 … … 0.79 (0.69–0.90) 2.34×10−4 68.2
Stage 2 replication
  United Kingdom 716 1078 0.111 0.113 0.98 (0.79–1.21) 0.84 …
  Denmark 490 172 0.077 0.140 0.52 (0.36–0.77) 8.86×10−4 …
  Combined 1206 2456 … … 0.73 (0.57–0.94) 0.014 87.3
Combined stages 1 and 2 replication 2498 32 959 … … 0.78 (0.69–0.87) 1.95×10−5 74.3
New Zealand genome-wide study 885 1000 0.062 0.088 0.68 (0.50–0.93) 0.005 …
All combined 5138 39 273 … … 0.76 (0.70–0.83) 2.08×10−10 61.0
AF indicates allele frequency; CI, confidence interval; and OR, odds ratio.
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homeostasis and AAA pathogenesis may be productive in 
identifying therapeutic and preventative strategies.
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CLINICAL PERSPECTIVE
Abdominal aortic aneurysm (AAA) is a common cardiovascular disease that carries a high risk of mortality in the event of 
rupture. It can cluster in families, and a family history of the disease is associated with increased risk. The aim of genomic 
studies of AAA is to identify genetic variants that affect the disease process. This will further the understanding of the 
pathogenesis of the disease and potentially highlight molecules and biological pathways as possible therapeutic targets, 
biomarkers, or risk markers. In a comprehensive reanalysis of our genome-wide study, we found that a genetic variant in 
the low-density lipoprotein receptor (LDLR) gene is associated with risk of AAA. The LDLR gene is important in other 
cardiovascular diseases and traits. Mutations of this gene cause familial hypercholesterolaemia, and common variations of 
the gene are associated with coronary artery disease risk. The rs6511720 polymorphism that we found to be associated with 
AAA is one of the most important genetic variants associated with serum LDL-cholesterol concentrations. However, despite 
several studies of this subject, the role of LDL-cholesterol in AAA pathogenesis remains controversial and unproven. By 
showing that an LDLR polymorphism is associated with AAA, our study suggests that function of the LDLR receptor might 
be important in the pathogenesis of AAA, which may be mediated through LDL-cholesterol levels or other functions of the 
protein. Future studies will be required to understand the functional basis for the association observed.
 by guest on February 13, 2017
http://circgenetics.ahajournals.org/
D
ow
nloaded from
 
Sayers, Panos Deloukas, Nilesh J. Samani and Matthew J. Bown
Powell, Per Eriksson, Kári Stefánsson, John R. Thompson, Steve E. Humphries, Robert D.
Simon Potter, Jes S. Lindholt, Jonathan Golledge, Paul E. Norman, Andre van Rij, Janet T. 
de Graaf, Lambertus A. Kiemeney, John B. Wild, Sarah Edkins, Rhian Gwilliam, Sarah E. Hunt,
Unnur Thorsteinsdottir, Jan D. Blankensteijn, Joep A.W. Teijink, Cisca Wijmenga, Jacqueline 
Frank M. van Bockxmeer, Matthew Waltham, Stefán E. Matthíasson, Gudmar Thorleifsson,
Robert A.S. Ariëns, Anne Johnson, Soroush Sohrabi, Alberto Smith, Matthew M. Thompson, 
Burnand, Anne H. Child, Rachel E. Clough, Gillian Cockerill, Hany Hafez, D. Julian A. Scott,
Benjamin J. Wright, Suzannah Bumpstead, Annette F. Baas, Sólveig Grétarsdóttir, Kevin 
Declan T. Bradley, Anne E. Hughes, Stephen A. Badger, Gregory T. Jones, Seamus C. Harrison,
 Is Associated With Abdominal Aortic AneurysmLDLRA Variant in 
Print ISSN: 1942-325X. Online ISSN: 1942-3268 
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Dallas, TX 75231
is published by the American Heart Association, 7272 Greenville Avenue,Circulation: Cardiovascular Genetics 
doi: 10.1161/CIRCGENETICS.113.000165
2013;6:498-504; originally published online September 17, 2013;Circ Cardiovasc Genet. 
 http://circgenetics.ahajournals.org/content/6/5/498
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 http://circgenetics.ahajournals.org/content/suppl/2013/09/17/CIRCGENETICS.113.000165.DC1
Data Supplement (unedited) at:
  
 http://circgenetics.ahajournals.org//subscriptions/
is online at: Circulation: Cardiovascular Genetics  Information about subscribing to Subscriptions:
  
 http://www.lww.com/reprints
 Information about reprints can be found online at: Reprints:
  
document. Permissions and Rights Question and Answer information about this process is available in the
requested is located, click Request Permissions in the middle column of the Web page under Services. Further
Center, not the Editorial Office. Once the online version of the published article for which permission is being 
 can be obtained via RightsLink, a service of the Copyright ClearanceCirculation: Cardiovascular Geneticsin
 Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
 by guest on February 13, 2017
http://circgenetics.ahajournals.org/
D
ow
nloaded from
 
1 
SUPPLEMENTAL MATERIAL 
 
Supplemental Methods 
Discovery Study Quality Control 
The microarray manufacturer provided a list of SNPs that have been reported to show 
discordant clustering due to beadpool changes between genotyping platforms used, which 
resulted in exclusion of 47 SNPs. One sample with low signal-to-noise ratio (<5) in crlmm 
was excluded. Base calls with a probability confidence of <90% were excluded. One hundred 
and fifty three individuals were excluded as relatives (>12.5% identical) or duplicates. 
Principal components analysis was conducted using Eigensoft v3.0 with reference to the 11 
populations in the HapMap phase 3 data release,1 and 428 individuals with outlying ancestry 
were excluded (Supplementary Figure 1). Individuals with a genotyping rate < 99% were 
excluded. Those with an inbreeding coefficient >0.08 (suggestive of a sample problem) or <-
0.08 (suggesting contamination) were excluded. 
Case and control samples were genotyped at different times using different platforms, 
which can cause systematic differences in genotyping,2 and is a potential source of false 
associations in this study. It was therefore necessary to apply marker-level quality control 
measures to the case group as well as the control group. SNPs with minor allele frequency 
<1% in case or control groups were excluded. SNPs with overall genotyping rate <99% were 
excluded. Assessment for deviation from Hardy Weinberg equilibrium was conducted using 
the method of Wigginton et al.3 as implemented in PLINK v1.07. Stringent arbitrary Hardy 
Weinberg equilibrium (HWE) thresholds for exclusion were applied (controls, P<0.01, 
16,664 SNPs; cases, P<1x10-4, 6,641 SNPs) to avoid detection of false associations. Seven 
thousand and sixteen SNPs with P<0.05 for informative missingness were excluded. To 
identify aberrant results due to technical problems, case and control genotype counts were 
2 
each separately compared to HapMap Phase 3 CEU counts using allelic chi-squared tests. 
Arbitrary thresholds (P<1x10-3 for controls, 7,160 SNPs; P<1x10-10 for cases, 793 SNPs) 
were used to exclude from further analyses SNPs that may have been unreliably genotyped, 
with a less stringent threshold for cases to allow for true differences due to the phenotype.  
After the association analysis was conducted, SNPs with association P< 1x10-4 were 
excluded if there was not a further association with P<1x10-4 within 100kb. This resulted in 
exclusion of 138 SNPs. Cluster plots of normalised intensity and genotype were inspected for 
the remaining SNPs with P<1x10-4. Correction for genomic inflation (λ=1.03) was conducted 
using the median chi-square in PLINK.4 All further analyses were based on corrected P 
values. SNPs in or near LRP1, IL6R and CDKN2B-AS (genes known to be associated), and 
GPC6 (which we investigated previously11) were not carried through to the replication study. 
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Supplementary Table 1. Discovery Genome-wide Association Study Results 
CHR SNP Position (base pairs) Effect allele MAF Cases MAF Controls Odds Ratio (95% CI) PGC 
1 rs4240872 152702819 G 0.25 0.22 1.21 (1.10 - 1.32) 7.21x10-5 
1 rs7514452 152704708 G 0.21 0.18 1.22 (1.11 - 1.34) 6.83x10-5 
2 rs4854251 95400974 C 0.19 0.16 1.23 (1.12 - 1.36) 5.53x10-5 
2 rs10874471 95401820 G 0.19 0.16 1.23 (1.12 - 1.36) 5.53x10-5 
4 rs12507728 11142794 A 0.44 0.49 0.84 (0.78 - 0.91) 1.14x10-5 
8 rs2597384 20594816 A 0.47 0.51 0.85 (0.79 - 0.92) 5.98x10-5 
8 rs12680047 128828043 G 0.33 0.37 0.84 (0.77 - 0.91) 2.79x10-5 
9 rs10116277 22071397 A 0.52 0.48 1.17 (1.09 - 1.27) 5.23x10-5 
9 rs4977574 22088574 G 0.53 0.48 1.19 (1.10 - 1.28) 1.76x10-5 
11 rs11031122 30504014 G 0.29 0.25 1.21 (1.11 - 1.32) 2.03x10-5 
11 rs11031125 30509905 A 0.29 0.25 1.20 (1.11 - 1.31) 2.84x10-5 
11 rs495997 100440990 G 0.37 0.41 0.85 (0.79 - 0.92) 8.89x10-5 
12 rs4759044 55816937 G 0.42 0.46 0.85 (0.79 - 0.92) 5.40x10-5 
12 rs1466535 55820737 A 0.32 0.37 0.84 (0.77 - 0.91) 2.12x10-5 
13 rs9301909 93247199 A 0.33 0.29 1.20 (1.10 - 1.30) 2.14x10-5 
13 rs2892667 93254940 G 0.33 0.29 1.20 (1.10 - 1.30) 2.56x10-5 
13 rs9524249 93281734 C 0.33 0.29 1.20 (1.10 - 1.30) 2.34x10-5 
13 rs1411513 93317951 A 0.33 0.29 1.20 (1.10 - 1.30) 2.55x10-5 
13 rs9524264 93326419 C 0.36 0.32 1.18 (1.09 - 1.28) 6.59x10-5 
15 rs12441037 58889949 G 0.03 0.05 0.64 (0.52 - 0.79) 6.49x10-5 
15 rs6494226 58893178 A 0.03 0.05 0.64 (0.52 - 0.79) 5.59x10-5 
19 rs6511720 11063306 A 0.10 0.12 0.76 (0.67 - 0.86) 3.05x10-5 
19 rs2228671 11071912 A 0.10 0.13 0.77 (0.68 - 0.88) 8.37x10-5 
CHR, chromosome; SNP, single nucleotide polymorphism; MAF, minor allele frequency; CI, confidence interval; PGC, P value corrected for 
genomic inflation.
4 
Supplementary Table 2. Results of in silico stage 1 replication study. 
SNP, single nucleotide polymorphism; OR, odds ratio; P, P value; *Han Eskin random effects meta-analysis performed in the presence of 
heterogeneity, otherwise fixed effects meta-analysis.
  Netherlands Iceland Meta-analysis 
SNP 
Effect 
allele OR P OR P OR P I2 
rs10874471 G 0.97 (0.83 - 1.13) 0.68 0.96 (0.80 - 1.14) 0.63 0.96 (0.84 - 1.09) 0.54 0 
rs12507728 A 0.89 (0.80 - 0.99) 0.039 1.12 (0.98 - 1.28) 0.087 1.00 (1.00 - 1.01) 0.12 85.2* 
rs2597384 C 0.90 (0.81 - 1.01) 0.068 1.02 (0.89 - 1.17) 0.77 0.95 (0.92 - 1.08) 0.23 45.1* 
rs12680047 G 1.01 (0.90 - 1.12) 0.93 1.08 (0.94 - 1.25) 0.24 1.04 (0.94 - 1.15) 0.43 0 
rs11031125 A 0.97 (0.85 - 1.09) 0.58 0.98 (0.84 - 1.15) 0.84 0.97 (0.87 - 1.08) 0.58 0 
rs495997 G 0.88 (0.78 - 0.98) 0.019 0.93 (0.80 - 1.07) 0.28 0.89 (0.82 - 0.98) 0.012 0 
rs6494226 A 1.85 (1.18 - 2.89) 7.0x10-3 0.69 (0.41 - 1.17) 0.16 1.14 (1.01 - 1.30) 0.041 87.2* 
rs6511720 A 0.70 (0.59 - 0.83) 5.7x10-5 0.91 (0.72 - 1.15) 0.41 0.79 (0.69 - 0.89) 2.34x10-4 68.2* 
5 
Supplementary Table 3. Sequenom iPLEX Oligonucleotides 
SNP Primer Sequence 
Extension 
Direction 
rs6511720 Extension CCTAAGACTTCCTTAACATTTT Reverse 
rs6511720 Primer-1 ACGTTGGATGGTGTATCTCACTCACCAATC  
rs6511720 Primer-2 ACGTTGGATGAACAAGGCCTTGCCTAAGAC  
 
 
 
Supplementary Table 4. rs6511720 A and AAA in the UK and Denmark Replication Studies 
with Adjustment. 
Study 
(Adjustment) 
Cases Controls Odds Ratio (95% 
Confidence Interval) 
P 
UK (Age) 714 1076 1.03 (0.82 – 1.29) 0.80 
Denmark (Age) 490 172 0.52 (0.36 – 0.77) 8.9x10-4 
New Zealand 
(Age) 
885 1,000 0.68 (0.50 – 0.93) 0.016 
New Zealand 
(LDL-cholesterol) 
885 1,000 0.69 (0.52 – 0.92) 0.012 
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Supplementary Figure 1 Principal components analysis of the study population with reference 
to HapMap populations 
Principal components analysis of the study population with reference to the International 
HapMap populations, showing first and second axes, and first and third axes plotted, before (left) 
and after (right) removal of population outliers. ASW, African ancestry in Southwest USA; 
CEU, Utah residents with Northern and Western European ancestry from the CEPH collection; 
CHB, Han Chinese in Beijing, China; CHD Chinese in Metropolitan Denver, Colorado; GIH, 
Gujarati Indians in Houston, Texas; JPT, Japanese in Tokyo, Japan; LWK, Luhya in Webuye, 
Kenya; MEX, Mexican ancestry in Los Angeles, California; MKK, Maasai in Kinyawa, Kenya; 
TSI, Toscans in Italy; YRI, Yoruba in Ibadan, Nigeria. 
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Supplementary Figure 2. Quantile-quantile plot of logistic regression P values 
Quantile-quantile plot showing P values before (black) and after (green) correction for genomic 
inflation. 
 
 
